MedPath

Estrogen Treatment in Acromegalic Women

Phase 2
Conditions
Acromegaly
Registration Number
NCT00315107
Lead Sponsor
Université de Montréal
Brief Summary

Oral estrogens may be an effective adjuvant treatment for control of acromegaly in patients with resistance to somatostatin analogs.

Detailed Description

This will be a canadian multicenter study with a randomized, double-blind, placebo-controlled design, to assess the efficacy and safety of adjuvant alesse in female acromegalic patients with suboptimal response to sandostatin LAR treatment.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
30
Inclusion Criteria
  • Women 18 years and older treated with somatostatin analogs
  • Active acromegaly
Exclusion Criteria
  • Cardiovascular or cerebrovascular disease
  • Thrombophlebitis or thromboembolism
  • Breast cancer
  • Non-controlled arterial hypertension
  • Smoking
  • Pregnancy or lactation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

CHUM - Notre-Dame Hospital

🇨🇦

Montreal, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath